A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Romidepsin (Primary) ; Cisplatin; Dexamethasone; Gemcitabine
  • Indications Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
    • 06 Dec 2016 Results assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top